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A B S T R A C T 
The concomitant occurrence of chronic myeloid leukemia and pregnancy is uncommon and projected to be one in 
75000-100000 pregnancies annually. We present a case of 28 years old lady with 36 weeks of gestation diagnosed as 
chronic myeloid leukemia in chronic phase. Her pregnancy was uneventful and she delivered a healthy male baby. 
She breast fed the baby for 3 weeks before initiating treatment for chronic myeloid leukemia. Close vigilance and 
relevant investigations are of paramount importance in recognizing this extremely rare disease during pregnancy.  
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Introduction 
Chronic  myeloid  leukemia  (CML)  is  a  clonal  stem 
cell disorder characterized by increased proliferation 
of myeloid elements at all stages of differentiation. It 
is characterized by two distinct clinical stages. The 
first (chronic) stage is marked by a proliferation of 
myeloid cells showing full range of maturation and 
eventually  a  decrease  in  myeloid  differentiation 
generally  occurs  as  the  disease  enters  an  advanced 
state (accelerated stage or blastic stage) with a very 
poor prognosis.
[1] The incidence of chronic myeloid 
leukemia  in  pregnancy  is  one  is  75000-100000 
pregnancies with a risk of leucostasis, blast crisis and 
placental  insufficiency  with  consequent  low  birth 
weight,  fetal  prematurity  and  increased  mortality.
[2] 
We  report  a  case  of  a  28  years  lady  diagnosed  as 
chronic  phase  of  CML  in  36  weeks  of  gestation 
delivering a healthy male baby in a teaching hospital, 
Sri  R.L.  Jalappa  Hospital  and  Research  centre 
attached to Sri Devaraj Urs Medical College. 
 
Case history 
A 28 years old woman, gravida 3, parity 2 and living 
2 with 36 weeks of gestation presented with labour 
pains.  Her  antenatal  period  was  uneventful. 
Menstrual  cycles  were  regular.  Routine  hemogram 
revealed  a  total  leucocyte  count  of  1,03,000 
cells/cumm, hemoglobin 11.7g/dl, platelets 2,67,000 
cells/cumm,  neutrophils  64%,  myelocytes  10%, 
metamyelocytes 6%, myeloblasts 2%, lymphocytes. 
 Figure-1: Peripheral blood smear of CML in chronic
 phase. (Leishman, x1000)  
 
Figure-2: Scatter diagram of CML 
 
 
14%, basophils 4% (Figure-1). She was diagnosed as 
a case of CML-chronic phase in labour. She delivered 
a  normal  healthy  male  baby  weighing  2.5  kg  with 
Apgar score of 7 at 1 minute and 8 at 5 minutes with 
no  abnormality  and  blood  counts  were  normal. 
Repeat Hemogram was done 24 hours after delivery 
which  revealed,  total  leucocyte  count  
GJMEDPH, Vol 1(4) July- August 2012  Page 60 
 
88,000cells/cumm,  Hemoglobin  10.8g/dl  and 
platelets  3,60,000  cells/cumm  (Figure-2). 
Ultrasonography of abdomen after delivery showed 
splenomegaly.  Bone  marrow  examination  revealed 
hypercellular  bone  marrow  with  increased 
granulopoiesis  and  2  %  blasts.  Cytogenetic  study 
(46XY,  t(9;22)  (q34;q11),  bcr/abl  positive), 
confirmed the diagnosis of chronic phase CML. The 
child  was  breastfed  for  3  weeks  before  starting 
therapy for chronic phase CML.                                                                                                                                                                                                                                                                                                                  
 
Discussion 
Leukemia during pregnancy is very uncommon. CML 
accounts for less than 10% of all leukemias during 
pregnancy.
[3]  Usually,  the  diagnosis  is  made 
incidentally during a routine complete Hemogram for 
unrelated  reasons.  Patients  usually  present  with 
weakness, malaise and abdominal discomfort due to 
splenomegaly.
[4]  Diagnosis  is  usually  based  on 
peripheral  blood  leucocytosis  with  basophilia  and 
eosinophilia  which  is  further  confirmed  on  bone 
marrow examination and detection of a Philadelphia 
(Ph)  chromosome  and/or  the  BCR-ABL 
rearrangement.  Philadelphia  chromosome  can  be 
detected  by  conventional  chromosomal  analysis, 
molecular  cytogenetic  detection  of  gene 
rearrangement  applying  fluorescent  in  situ 
hybridisation  and  molecular  genetic  analysis  of 
fusion products using polymerase chain reaction.
[5]  
Management  of  CML  during  pregnancy  is  difficult 
for  patients,  their  families  and  care  providers  and 
hence  treatment  of  CML  and  pregnancy  remains  a 
clinical  challenge.  There  is  no  evidence  that  the 
behaviour of chronic myeloid leukemia is altered in 
pregnancy.
[6] However there is a risk of leukostasis 
and placental insufficiency with consequent low birth 
weight, foetal prematurity and increased mortality if 
CML is left untreated during pregnancy. There have 
been  few  reports  of  successful  treatment  of  CML 
during  pregnancy  by  therapeutic  agents  like 
hydroxyurea,  bulsulfan,  interferon  α,  imatinib  and 
bosutinib.  Leukapheresis  is  also  being  tried  in  few 
cases.  However  there  has  been  no  systemic 
investigation of the effect of these therapeutic options 
in  pregnancy.
[7]   Recommendations  of  medical  care 
for  the  future  pregnancy  should  include  detailed 
description of possible risks to the patient and fetus 
which  includes  possible  birth  abnormalitites,  birth 
defect, deformities and/or termination of pregnancy. 
[8] 
 
Conclusion: 
Historical  evidence  shows  a  median  survival  of 
patients  with  untreated  CML  is  approximately  30 
months,  and  does  not  evolve  very  rapidly  at  the 
clinical  levels.
[9]  Hence  resistance  or  disease 
progression is unlikely to occur during the relatively 
short period of pregnancy and thus the case can be 
managed  by  close  observation  without  active 
intervention in  the best interest of both the  mother 
and fetus. However if there is presence of symptoms, 
a  rapidly  increasing  leucocyte  count  or  emerging 
signs of a more advanced disease will mandate the 
need for immediate therapy. 
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